There are two main points of control during the eukaryotic cell cycle, one acting in GI for onset of S and a second acting in G2 for onset of mitosis. In broad outline the latter control is now understood at least in part, and involves the p34CdC2 protein kinase which becomes activated during mitosis. A genetical approach for investigating the transition from mitosis through GI into S-phase in the simple eukaryote fission yeast will be described. Two gene functions are required for proper exit of mitosis, cndlt which encodes a DNA methyl cytosine transferase and dcdlt which encodes an RCCI like protein. A new gene rumlt has been discovered which regulates onset of S-phase. Over-producing rumlt locks the cell in a replicating state leading to nuclei of greatly increased ploidy. This regulation operates through the start control which commits cells to the cell cycle and involves the p34cdc2 protein kinase and the p85cdclo transcription factor. The mos proto-oncogene product, pp39mos, is required for meiotic maturation in vertebrate oocytes and is an active component of cytostatic factor (CSF), an activity that is responsible for arrest of meiosis at metaphase II. CSF is thought to arrest egg development at M-phase by stabilising M-phase promoting factor (MPF). Thus, the mos product functions at a major cell cycle control point, and its activity is directly or indirectly responsible for the stabilisation of MPF. This direct link between proto-oncogene function and M-phase cell cycle regulation could be responsible for certain phenotypes of mos transformed cells. RB and its related proteins, p107 and p300, are nuclear constituents which can form stable complexes with certain transforming proteins of DNA Tumour Viruses. Proteins such as SV40 T antigen and the Adenovirus El A protein can form complexes with all three proteins, and complex formation correlates strongly with the ability of these proteins to serve their transforming functions. Moreover, from detailed biological and in vivo and in vitro structure-function analyses of RB, p107 and p300, it seems clear that these proteins operate to regulate key events in the cell cycle. Binding to Br. J. Cancer (1993), 68, 436-445 '." Macmillan Press Ltd., 1993 Although pRB has been intensively studied in recent years, we still know very little about its actual biochemical function. However, we have begun to understand some of the basic characteristics of the signal transduction pathway in which pRB acts. The upstream regulation of pRB appears to be controlled at least partially by protein phosphorylation. One form of pRB is the un-or underphosphorylated species that is found primarily in the GI phase of the cell cycle. As cells move into late Gl and S phase, pRB is phosphorylated by a cyclin-dependent kinase.
We have found that mos product is associated with and phosphorylates tubulin in vitro. Our analyses have also shown that 1B-tubulin is preferentially associated with and phosphorylated by the Xenopus mos product prepared from either transformed cells or unfertilised eggs. Immunofluorescence and immunoelectron microscopy analyses have shown that the mos product in transformed cells colocalises with tubulin in microtubules as well as in the metaphase spindle and early telophase mid-body and asters. We speculate that the mos product may contribute to the formation of the spindle pole as well as the spindle and thereby contribute (as CSF) to metaphase arrest.
Constitutive expression of mos in somatic cells is responsible for morphological transformation. Only cells expressing low levels of pp39mos can grow as transformed cells. We postulate that this amount of product is not sufficient to cause mitotic arrest but is enough to impart M-phase phenotypes during interphase. Altered cell morphology and loss of contact inhibition during interphase could be due to cytoskeletal changes that normally occur during mitosis. Furthermore, the transformed phenotype may be mediated through M-phase modification of interphase microtubules by pp39mOs. Checkpoint genes, as first described by Weinert and Hartwell, function as pauses in the cell cycle to allow the fidelity of the process to be checked. We have proposed that oncogenes with downstream M-phase activity, compromise cell cycle checkpoint functions. This could be responsible for the genetic instability of tumor cells as well as provide an explanation for how antineoplastic drugs work. Research sponsored by the National Cancer Institute, DHHS, under RB and its related proteins, p107 and p300, are nuclear constituents which can form stable complexes with certain transforming proteins of DNA Tumour Viruses. Proteins such as SV40 T antigen and the Adenovirus El A protein can form complexes with all three proteins, and complex formation correlates strongly with the ability of these proteins to serve their transforming functions. Moreover, from detailed biological and in vivo and in vitro structure-function analyses of RB, p107 and p300, it seems clear that these proteins operate to regulate key events in the cell cycle. Binding to one or another viral transforming protein can block one or more aspects of their growth controlling function. Since RB and p107 operate, at least in part, by forming complexes with one or more transcription factors, at least one or which, itself, does seemingly important cell cycle work, it seems likely that part of their control over key cell cycle switch points is manifest by the modulation of the action of their transcription factor targets. The potential mechanisms which regulate the ability of RB to affect the behaviour of the transcription factor, E2F -a major RB and p107 binding target, to deliver a growth suppressing signal towards the end of GI, and to modulate E2F transactivation function will be discussed. Small DNA tumour viruses, such as adenovirus, encode proteins that are potent transforming agents when tested in standard oncogenic assays. For adenovirus the best characterized viral oncoproteins are the early region lA (ElA) products. Introducing the ElA gene into primary cells leads to the establishment of immortal cell lines. When EIA is introduced in conjunction with the appropriate cooperating oncogenes, the recipient cells become fully transformed. The regions of EIA that are required for its oncogenic potential have been determined, and they correspond to the regions that allow ElA to bind to a number of cellular polypeptides. This correlation of structure and function suggests that these cellular proteins are the targets for ElA-mediated transformation. There are 11 proteins that are known to bind either directly or indirectly to EIA, and 4 of these proteins have now been identified. The 105 Kd protein is the product of the retinoblastoma tumour suppressor gene (pRB), the 107 Kd protein (p1O7) is a relative of pRB, the 60kD protein is cyclin A, and the 33 Kd protein is cyclin-dependent kinase 2 (cdk2), a protein closely related to the cell cycle-regulating kinase cdc2.
Although pRB has been intensively studied in recent years, we still know very little about its actual biochemical function. However, we have begun to understand some of the basic characteristics of the signal transduction pathway in which pRB acts. The upstream regulation of pRB appears to be controlled at least partially by protein phosphorylation. One form of pRB is the un-or underphosphorylated species that is found primarily in the GI phase of the cell cycle. As cells move into late Gl and S phase, pRB is phosphorylated by a cyclin-dependent kinase.
Only one target of pRB is well characterised and this is the transcription factor E2F. At least for some promoters, pRB acts as a negative regulator of transcription by binding to E2F and holding it in an inactive state. In some circumstances E2F also associates with the pRB-related p107 protein. Both the pRB/E2F and plO7/E2F complexes are found in distinct portions of the cell cycle. In Deregulated expression of the cyclin Dl gene is a feature of several types of tumour. For example, the gene is modestly amplified in about 15% of primary human breast cancers and squamous cell carcinomas. Although amplification leads to over-expression, cyclin Dl is only one of several candidate oncogenes on the > 1500 kb of DNA that is typically amplified. The evidence for a direct role is more persuasive in parathyroid adenomas where the gene is activated by a chromosomal rearrangement that juxtaposes the cyclin DI and parathyroid hormone genes. In certain B-cell tumours, particularly centrocytic lymphoma, expression of the gene is affected by a reciprocal translocation between the BLC-J locus on chromosome 1 1q13 and the immunoglobulin heavy chain on 14q23. Although a considerable distance from the breakpoint on 1 1q13, it appears that cyclin D1 is the target oncogene for the BCL-1 translocation. Similarly, the mouse homolog of cyclin Dl gene lies close to Fis-J, a proviral insertion site in Friend MuLV-induced lymphomas. The exact synteny between the corresponding regions of mouse chromosome 7 and human chromosome 11q13 suggests that disruption of Fis-l may be functionally analogous to the BCL-J translocation.
To better understand the role of cyclin DI in these tumours, we examined the expression of the gene and of its close relatives, cyclins D2 and D3, in a variety of haematological malignancies. The patterns of expression suggest that the three genes are independently regulated but there is considerable overlap in many cell types. To determine whether their functions also overlap, we have prepared specific antipeptide sera in order to assess interactions between the cyclin D family and other cellular proteins. Of particular interest are potential associations with cdc2-related protein kinases, via the conserved sequences in the so-called 'cyclin box'. Recent data suggest that the D-type cyclins may be regulatory subunits for the PSK-J3/cdk4 kinase rather than cdc2 or cdk2, but cyclin D immunoprecipitates contain at least two additional proteins that react with an antibody against the PSTAIRE motif. This multiplicity of cyclin-kinase partnerships will be discussed in relation to the oncogenic potential of the D cyclins. Human papillomavirus type 16 (HPV16) infection is associated with most ano-genital cancers and two virally encoded proteins, E6 and E7, appear to play a role in the development and maintenance of these malignancies. Both E6 and E7 display transforming and immortalising activities in rodent and human cells and the mechanisms by which these viral proteins function are related to their ability to form complexes with host proteins normally involved in regulating cell growth. E6 has been shown to bind and target the tumour suppressor protein p53 for rapid degradation (Scheffner et al., 1990 , Cell, 63, 1129 and the importance of this interaction in malignant development is strongly supported by the inverse correlation between presence of HPV and somatic p53 mutations in primary human ano-gential cancers. These studies indicate that the loss of wild type p53 following E6 expression is sufficient to allow the development of a primary cancer, although further analyses have indicated that somatic mutation resulting in the expression of a mutant p53 protein may still play a role in the metastatic progression of HPV positive primary cervical cancers. All of the mutant p53s detected in ano-gential cancers acquired transforming activities, although their ability to bind and be targeted for degradation by E6 varied. Interestingly, p53 mutants detected in HPV positive metastases showed some resistance to E6 mediated degradation. HPV16 E7 also interacts with a number of cell proteins which are involved in cell cycle regulation. In addition to the previously described interaction with the RB protein (Dyson et al., 1989, Science, 243, 934) , we have recently shown an association of E7 with the RB related p107 protein and a cell cycle regulated histone HI kinase activity. Analysis of mutant proteins has shown that a similar region of E7 participates in each of these associations, although subtle differences in the sequence requirements for RB and p107 binding can be detected. Since this region of E7 is also necessary for transforming activity it seems likely that some, or all, of these interactions are necessary for the biological activity of the E7 protein. TNFa has been shown to be cytotoxic to several transformed cell lines. In the present study we have investigated its effect on four human cervical cancer cell lines -HeLa, Sitta, C33-A and HOG-1. Cells were cultured in Phenol Red-free DME/ F12 medium +2% DCCFCS ± TNFa for 4 days. TNFa inhibited HOG-1 proliferation, determined by both cell counting and DNA content, in a dose dependent manner and at 10 ng/ml caused a maximum inhibition of 50%. However TNFa only caused a weak inhibition of HeLa cell growth (15% at 10 ng/ml) and had no effect on Sitta or C33-A cells even at 100 ng/ml. Inhibition of HOG-1 cell proliferation by TNFa was blocked by 10 nM dexamethasone and suggested that Phospholipase A2, which is inhibited by glucocorticoids, could be involved in TNFa cellular signalling in these cells. In a number of cell types TNFa has been shown to induce programmed cell death (apoptosis) We have examined the relationship between the products of the p53 gene and c-myc and pan-ras proto-oncogenes and cellular proliferation kinetic parameters measured by BrdU incorporation in 18 human in vitro cell lines of different histological origin. A wide range of potential doubling times was apparent, varying between 10 and over 40 hours and the duration of S-phase was from 6 to 20 hours.
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A strong correlation between the labelling index and the ploidy (as measured by the index of cell line DNA to that of diploid cells) was seen in the 18 cell lines examined (r = -0.6272 p = 0.005). Cell lines with a lower ploidy had a greater proportion of cells in S-phase and there was also a correlation between the potential doubling time (Tpot) and DNA ploidy (r = 0.582, p = 0.011). Thus cells with a lower ploidy were observed to proliferate more rapidly than those with a high ploidy.
Actin, topoisomerase II and c-raf-l gene products did not show any correlation with cell cycle kinetic parameters.
Both c-myc (r = 0.4247, p = 0.078) and pan-ras (r = 0.42, p = 0.08) showed correlations with the labelling index with values close to significance. Combining c-myc and pan-ras, however, did not increase the level of their correlation with the labelling index suggesting that they were acting as independent variables. C-myc levels also showed a correlation with Tpot (r = -0.4503, p = 0.06) and the duration of S-phase (r = -0.459, p = 0.055) in that high c-myc levels appeared to be associated with faster S-phase transit and a faster doubling time. High p53 levels by contrast correlated with slower S-phase transit times. Demembranated sperm heads, detergent-isolated somatic nuclei and even naked DNA are efficiently replicated in cytoplasmic extracts of activated amphibian eggs, but only after nuclear assembly and the formation of an intact nuclear envelope.'-4 DNA synthesis has not previously been shown to be initiated in high-speed (100,000g) supernatants of egg cytoplasm because they do not contain the vesicular material required to support nuclear envelope formation.3 Here we show that mammalian nuclei prepared by scrape-lysis are able to initiate DNA replication in such high-speed supernatants. These nuclei being DNA synthesis asynchronously. This asynchrony cannot be attributed to differences in the time taken for nuclear assembly as previously supposed.'-2 Instead, we suggest that the asynchrony reflects intrinsic differences between nuclei and that these differences are a major cause of cell cycle variability. Our demonstration of initiation in high-speed supernatants now enables the initiation of eukaryotic DNA synthesis to be studied in the absence of nuclear assembly. There is current interest in the biology of ductal carcinoma in situ (DCIS) both because it is the earliest recognisable phase of mammary carcinoma and as a possible guide to treatment for the increasing number of cases now being detected in the National Breast Cancer Screening programme. The histological classification is currently based on ill defined architectural features. Correlation between biological markers, including various proliferation indices, and histological patterns have been demonstrated. Most studies, however, have been small and have only looked at one or two markers. We have examined 102 cases of pure DCIS using a carefully defined classification based on cell morphology and histological architecture and evaluated four biological markers using immunohistochemistry. The results show strong correlation between histological classification and all the biological markers, as well as between the individual markers. The most significant correlation with histological subtype was found with the expression of the proliferation antigen KiSl, followed respectively by the expression of progesterone receptor, c-erbB-2 oncoprotein and mutant p53 protein. These findings may be of significance in planning future treatment protocols for DCIS. Overexpression of the c-erbB-2 oncoprotein has been shown to adversely influence prognosis in human breast cancer. As a growth factor receptor, it is possible that this effect is mediated via increased cellular division. We have therefore studied the relationship between c-erbB-2 expression and proliferative activity of breast tumours.
Seventy-three women with breast cancer were given 200 mg of the thymidine analogue bromodeoxyuridine (BUDR) 4-10 hours prior to surgery. Alcohol fixed tumour samples were enzymatically disaggregated and stained for DNA content and BUDR content. Multiparameter flow cytometry enabled measurement of tumour ploidy, the proportion of cells in S phase (labelling index, LI), length of S phase (Ts), and potential doubling time (Tpot). Immunohistochemical localisation of c-erbB-2 was carried out using the polyclonal antipeptide antibody 21N and an avidin-biotin system.
Twenty-eight tumours (38%) were positive for c-erbB-2. Thirty-two tumours (43%) were DNA diploid, and these were significantly less likely to be c-erbB-2 positive than DNA aneuploid tumours (x2 = 4.3, p = 0.04). Values of kinetic parameters were compared in c-erbB-2 positive and negative tumours using the Mann-Whitney statistic, with no significant difference in respect of LI (p = 0.28), Ts (p = 0.82) or Tpot (p = 0.51).
These data provide no evidence that expression of c-erb-2 provides a growth advantage in human breast cancer. Dysplasia of the tracheobronchial epithelium is considered a preneoplastic lesion. Proliferating cell nuclear antigen (PCNA) is expressed in the nuclei of cells in the cell cycle and has been studied by other groups in lung carcinoma. Using the immunocytochemical localisation of PCNA as a method of measuring proliferation we have noted marked differences in the expression of this antigen in normal and neoplastic cells from the bronchial tree. Forty-seven cases of bronchial dysplasia have been collected over the period [1981] [1982] [1983] [1984] [1985] [1986] [1987] [1988] [1989] by the Department of Histopathology at Broadgreen Hospital and these were studied with a monoclonal antibody raised against PCNA (PC10 DAKO) and compared with 32 cases of normal bronchial epithelium from a main bronchus. All cases have been reviewed and classified as a mild, moderate and severe. Out of the 47 cases, three showed mild dysplasia, 11 moderate dysplasia, 33 severe dysplasia. In each case a minimum of 100 nuclei per section were counted and the results expressed as percentage of positive nuclei. A twotailed Mann-Whitney test was performed comparing the results from normal bronchus to those of each group of dysplasia which showed no difference in the percentage of positive cells in mild dysplasia (P>0.1) but significant increase in the PCNA expression in moderate dysplasia (P = 0.01) and severe dysplasia (P<0.001). The mitotic indices of the dysplastic biopsies showed a significant correlation with the PCNA percentage (n = 47, r = 0.67, p = <0.00).
From these results we conclude that in moderate and severe dysplasia there is a marked increase in the number of cells with proliferating cell nuclear antigen and presumably cycling cells. This may indicate that in moderate and severe dysplasia the normal mechanisms of growth control have been lost. Radiolabelled amino acids combined with Positron Emission Tomography (PET) show promise for the accurate delineation of viable extent and may also provide a rapid and sensitive indicator of response to therapy. Promising early clinical reports led us to investigate the potential use of the amino acid analogue L-3-iodo-x-methyl tyrosine (IMT), which may be radioiodinated with isotopes suitable for PET or conventional single photon imaging. We have studied the biodistribution and kinetics of ['25I]IMT using two transplantable tumour systems in hooded rats, and compared the findings with those using the natural amino acid L-tyrosine (TYR) radiolabelled with tritium.
Preliminary studies using HSN tumours demonstrated maximum tumour uptake of IMT (0.85 ± 0.093% dose/gm, mean ± 1 s.d.) at 15 minutes post iv infusion and prolonged retention in tumour relative to normal brain tissue (TNRI5mm,, = 2.39 ± 0.21, TNR24hr = 7.43 ± 0.76). Brain uptake of IMT was found to be significantly reduced by competition with another large neutral amino acid phenylalanine, however, relatively less effect was seen in tumour and no change in IMT uptake was observed in skeletal muscle. Quantitative autoradiography revealed sharp delineation of the tumour boundary, and uniform IMT uptake was found even in poorly vascularised tumour regions, as confirmed by endothelial immunohistochemistry. IMT was found not to be incorporated into proteins.
Similar levels of IMT uptake were found using OES.HR1 tumours (Smith, T.A.D. et al., Br. J. Cancer, 1991, 64, p821) during growth stimulated by exogenous oestrogen. Following tumour growth arrest by removal of the oestrogen stimulus IMT uptake was seen to fall from 1.72 ± 0.42% to 1.00 + 0.39% dose/gm, however this was matched by a fall in tumour blood flow as estimated by 99"Tc-HMPAO distribution (1.07 ± 0.43% to 0.60 ± 0.33% dose/gm). Comparative studies using TYR also showed decreased radiotracer uptake in OES.HR1 tumours after growth arrest (0.87 ± 0.20 to 0.73 ± 0.16% dose/gm), and was associated with a similar reduction in 9'9Tc-HMPAO uptake (0.84 ± 0.17 to 0.57 + 0.13% dose/gm). Unlike IMT however, a substantial proportion of TYR uptake in tumours was found to be protein bound (51 ± 19%), with a reduced but significant level of incorporation being seen following tumour growth arrest (30 ± 15%).
We conclude that IMT kinetics are more strongly influenced by blood flow and diffusion than cell proliferation, and that these factors are also of significance when using radiolabelled natural amino acids. Our findings suggest that the clearance of non-bound radiotracer from tumours is likely to be slow, and may be beyond the limits of observation for short-lived radionuclides such as "C (t,1/2 = 20 mins) commonly used for clinical PET imaging. The presence of altered forms of the p53 tumour suppressor gene in tumours appears to be the most widespread genetic change in human malignancy. The occurrence of missense mutations in this gene lead to the synthesis of abnormal forms of its protein product. The latter are much more stable than the wild-type p53 protein, and can be readily detected by immunohistochemistry. Recent reports have demonstrated that 30% of high grade, and 10% of low grade nonHodgkin's lymphomas (NHL), show positive staining for p53, and thus suggest that mutations of p53 are relatively common in NHL, especially in high grade NHL. We have studied the p53 gene in a series of non-malignant hyperplastic reactive nodes, low grade NHL and high grade NHL. It had previously been observed in solid tumours that mutations in one allele of the p53 gene were often accompanied by the loss of the other allele, as indicated by monosomy of chromosome 17. In our series of NHL we found that very few NHL samples (>10%) had lost a copy of chromosome 17. We decided, however, to examine p53 for the presence of mutations, and used the technique of chemical mismatch cleavage (which should allow all mutations to be identified). PCR products representing exons 2-4, 5-6, 7-9 of the p53 gene were prepared from the lymph node biopsy samples, and then subjected to mismatch cleavage. We found that only 1/22 NHL samples exhibited a mutation, which indicated that point mutations of p53 might not be common events An immunohistochemical study for p53 has been carried out on 195 primary breast cancer patients, with a 10-year median follow-up. Anti-p53 polyclonal antibody CM-1 has been used with a peroxidase conjugated streptavidin biotin technique on formalin fixed paraffin embedded sections. The presence of p53 protein was indicated by positive staining of the tumour nuclei. In this pilot study it was found that patients with carcinomas which expressed p53 protein in the majority of their tumour cells (19% of cases) had a considerably worse prognosis than those who did not. The effect of the presence of the protein is seen on disease free interval, overall survival and survival after relapse and is seen in node negative, as well as node positive, patients. Furthermore, the effect is most apparent in patients with infiltrating lobular and grade II infiltrating ductal carcinomas who have a rather heterogeneous clinical behaviour and are difficult to subdivide on the basis of currently available markers. Cox multivariate analysis shows that p53 majority staining is second only to node status in significance of effect on overall survival. The retinoblastoma protein, pRB, is multiply phosphorylated in a cell cycle dependent manner and this is thought to control cell cycle progression. Actively cycling human cells contain partially phosphorylated pRB in early GI (GIA). The receptor for the iron transport protein transferrin, is commonly expressed on the cells of human carcinoma including breast cancer and breast cancer cell lines. As iron is an essential element of oxidative respiratory enzymes, cells in an actively dividing state require it's incorporation. Growth regulation of breast cancer cells is influenced by estrogen and to a lesser extent, by progesterone. Therefore the present study has examined primary breast tumours for the expression of transferring receptors (TR), estrogen receptor (ER), progesterone receptor (PgR) and epidermal growth factor receptor (EGFR), to see whether TR expression correlated with markers suggesting good growth control (ER, PgR) or with a marker (EGFR) associated with poorly differentiated tumours. Immunocytochemical staining was performed on 114 patients 72 of which were postmenopausal and 42 were premenopausal. Our results show a strong correlation between the expression of TR and ER (p <0.004) and between TR and PgR (p <0.002), irrespective of the menopause status. There were no significant correlations between EGFR with either TR or ER. The results suggest a possible relationship between TR expression and estrogen mediated growth regulation. For this reason TR may well be a favourable prognostic marker for predicting response to endocrine therapy in addition to its role as a marker for cell proliferation. [Hofmann et al., 1991, Cancer Res., 51, 5292; Birch et al., 1991, Cancer Res., 51, 6660] possibly by mimicking lymphocyte behaviour [Arch et al., 1992, Science, 257, 682] . In normal epithelial cells and CD44 transfected 3T3 cells, however, CD44 expression has been linked to proliferation [Alho & Urnderhill, 1989 , J. Cell Biol., 108, 1557 Flanagan et al., 1989, Immunology, 67, 167] . We asked whether the expression of CD44 in human cancer was also linked to proliferation.
Flash frozen biopsies were obtained from surgical specimens to three adenomatous polyps and 22 colorectal adenocarcinomas (19 primary and 3 metastatic). CD44 was detected by immunocytochemistry using monoclonal antibody F10-44-2, and proliferative areas defined by immunocytochemistry using Ki-67 monoclonal antibody [Gerdes et al., 1982, Int. J. Cancer, 31, 13] on serial sections.
Results showed that in normal colonic mucosa CD44 was expressed on proliferating cells in the lower third of the epithelial crypt. In tumours CD44 expression was consistently associated with proliferative areas irrespective of tumour stage of differentiation. Non-proliferating areas of the carcinomatous epithelium did not express CD44. There was no apparent association with tumour progression and non-malignant tumours were strongly positive.
CD44 was only associated with proliferation of epithelial cells. Stromal cells in the lamina propria and in the tumours often expressed CD44 but did not appear to be proliferating as defined by . This is consistent with observations that the CD44 cell adhesion molecule has distinct functions in different tissues.
Our work demonstrates that F10-44-2 defined CD44 is consistently expressed during proliferation by normal colorectal epithelial cells, non-malignant colorectal tumour cells and colorectal carcinoma cells. Metallothioneins (MTs) the ubiquitously expressed low molecular weight proteins with high affinity for heavy metal ions (e.g. zinc, copper, cadmium). MT over-expression in cancer cell lines has been associated with resistance to anticancer drugs and irradiation therapy. Attempts have been made to relate immunohistochemically detectable MT to tumour grade and its tendency to recur. Using a monoclonal anti-MT antibody, E9, we investigated in a retrospective study the MT profile of melanoma.
Paraffin-embedded, formalin fixed tissues were studied from 48 patients with melanoma using standard two step indirect immuno-peroxidase method. The cases comprised 43 superficial spreading melanoma (SSM) and five nodular melanoma (NM) in which the thickness of the tumours was 0.0 to 1.5 mm. The presence of MT was observed in 15 of 43 SSM and all 5 NM (P <0.002). Exposed regions (calf, arm) tended to show MT expression (15/28) more often than other regions (trunk 5/20) (P < 0.002). Melanomas less than 0.8 mm in thickness (i.e. with very low potential for metastasis) expressed MT in 29% as compared to 65% in melanomas thicker than 0.8 mm (P <0.002). This study suggests that MT expression is associated with potential for disease progression and thus might be used as a prognostic indicator. The naturally occurring polyamines are essential for cell growth and differentiation. They are found in high concentrations in rapidly growing and cancer cells and intracellular concentrations correlate with cell growth rates, as growth is decreased so polyamine content falls and vice versa. Indeed recent evidence suggests that loss of polyamines precedes any inhibition of growth implying a causal role for polyamines in preventing growth. The polyamine content of the cell is decreased by the interconversion of the higher polyamines to either monoacetyl derivatives or smaller amines carrying less charge, a process which may facilitate their excretion. In this study we have investigated the link between growth inhibition and polyamine acetylation, the first step in the interconversion pathway, in a human breast carcinoma cell line using the commonly used anticancer drug, doxorubicin (DOX), to limit cell growth.
T47-D cells were grown under standard cell culture conditions in Dulbecco's medium supplemented with 10% (v/v) foetal calf serum and insulin (8 pg/ml). Polyamine interconversion was measured as spermidine/spermine N-acetyltransferase (SAT) activity. Cell growth was measured as the change in protein content and polyamines were quantified by hplc.
DOX inhibited the growth of T47-D cells with an ID5, of about 1 JiM. Inhibition of growth was accompanied by a decrease of intracellular polyamine content. Cytosolic SAT activity increased after DOX treatment with the increase being almost exclusively an induction of the N'-SAT, the enzyme responsible for the acetylation of spermine and spermidine in the N' position. Previous reports have shown similar increases in N'-SAT activity in response to treatment with polyamine analogues however unlike these inducers DOX did not prolong significantly the half-life of the enzyme. DOX itself had no effect on SAT activity when added directly to the in vitro assay. The depletion of cellular polyamines by DOX is due to enhanced acetylation resulting in further degradation and/or excretion. It may be that stimulation of polyamine catabolism, and in particular N1-SAT activity, is an early event in the cellular response to growth limitation by this and other cytotoxic drugs. Antioestrogen therapy using tamoxifen has an established role in the management of breast cancer. Although used as an oestrogen antagonist, tamoxifen also exhibits intrinsic partial agonist activity, which might potentially reduce its clinical efficacy. ICI 182780 is a novel, steroidal antioestrogen, which is devoid of agonist activity and is currently undergoing clinical trial. We have investigated the antioestrogenic effects of 4-hydroxytamoxifen (Tam) and ICI 182780 (182) on MCF 7 breast cancer cells, using the CourtenayMills clonogenic assay, which measures the ability of cancer cells to grow as anchorage independant colonies in soft agar. The standard assay was modified by the use of serum-free media in order to optimise its sensitivity with respect to the effects of endocrine agents.
Using this assay we were able to demonstrate a significant increase in colony forming efficiency (CFE) in the presence of a physiological concentration (1 nM) of Oestradiol (E2) compared to control conditions. This oestrogenic stimulation was inhibited by both ICI 182780 and 4-hydroxytamoxifen in a dose dependant manner at concentrations between 10 nM and 1 gM. However We conclude that, in vitro, ICI 182780 produces a more complete inhibition of the growth of oestrogen responsive cells than 4-hydroxytamoxifen and may therefore offer potential therapeutic advantages in vivo for the treatment of advanced breast cancer. 5,6-Dimethyl xanthenone-4-acetic acid (5,6-dimethyl XAA) is a potent analogue of flavone acetic acid (FAA) and has been accepted for potential clinical evaluation by the Cancer Research Campaign, U.K. Like FAA, 5,6-dimethyl XAA appears to exert its antitumour effects indirectly through the stimulation of host responses. 5,6-dimethyl XAA, like FAA, stimulated the release of tumour necrosis factor (TNF), as detected using L-929 cells, and reduced blood flow in s.c. colon 38 and in i.m. mammary MCa4 tumours. 5,6-dimethyl XAA also stimulates nitric oxide formation, induces natural killer activity and increases bone marrow colony forming units in the mouse. These effects presumably all result from secretion of cytokines. The question of whether 5,6-dimethyl XAA stimulates formation of TNF in humans was approached in vitro by comparing cultures of mouse (J774) and human (HL-60) macrophage lines. In both of these lines, 5,6-dimethyl XAA stimulated the formation of larger amounts of TNF mRNA than did FAA, and also stimulated at a lower concentration. The question of whether 5,6-dimethyl XAA induces tumour haemorrhagic necrosis through the action of TNF was investigated by taking advantage of the observation that the serotonin antagonist cyproheptadine inhibits the induction of tumour haemorrhagic necrosis by TNF. Coadministration of cyproheptadine significantly inhibited both the induction of tumour haemorrhagic necrosis and the production of nitric oxide in response to 5,6-dimethyl XAA or FAA. Reduction of plasma serotonin concentrations, by pretreatment with reserpine and p-chlorophenylalanine, had a similar but less pronounced effect. It is concluded that both serotonin and TNF are important for the action of 5,6-dimethyl XAA and related compounds.
